HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Melancholic and atypical major depression--connection between cytokines, psychopathology and treatment.

AbstractBACKGROUND AND PURPOSE:
Growing scientific evidence indicates that there is a correlation between depression and alternations in the immune system. The main aim of the study was to investigate serum levels of Interleukin-6 (IL-6) and Tumour Necrosis Factor-alpha (TNF-α) in melancholic and atypical depressive patients during acute exacerbations of illness, compared to healthy subjects. The secondary aim was to explore a possible association between cytokine levels and clinical characteristics, as well as total duration of prior antidepressant treatment.
METHOD:
We measured serum levels of IL-6 and TNF-α in 47 patients suffering from major depressive disorder (MDD) (29 melancholic and 18 atypical) in exacerbation of illness, compared to 39 healthy controls, matched by sex, body mass index (BMI) and smoking habits. Serum levels of IL-6 and TNF-α were measured by enzyme-linked immunosorbent assay (ELISA). The severity of psychopathology was assessed using the Hamilton Depression Rating Scale (HDRS).
RESULTS:
IL-6 was significantly elevated in melancholic depressive patients (MDD-M) compared to healthy controls, while no difference was found between the patients with atypical depression (MDD-A) and the healthy group. Lower TNF-α serum level was found both in melancholic and in patients with atypical depression, compared with healthy subjects. We detected a positive correlation between cytokine levels in atypical, but not in melancholic subjects. Sex, age, smoking habits and BMI were not associated to cytokine levels in neither group. Clinical parameters (duration of illness, current episode, age of onset) were related to cytokine levels in atypical depression, while the duration of lifetime exposure to antidepressant treatment correlated to IL-6 serum levels in both melancholic and atypical depression.
CONCLUSION:
Our results suggest that the difference in pro-inflammatory cytokine levels could reflect a biological difference between melancholic and atypical depression. A positive correlation between the cytokines (TNF-α and IL-6) observed in depressive patients with atypical features, might be influenced by chronic course of illness, while IL-6 elevation could represent a state indicator for acute exacerbation, especially in melancholic patients. Total duration of antidepressant treatment could be a relevant factor influencing the immune status of patients who suffer either from melancholic or atypical depression.
AuthorsBojana Dunjic-Kostic, Maja Ivkovic, Nevena V Radonjic, Natasa D Petronijevic, Maja Pantovic, Aleksandar Damjanovic, Sanja Totic Poznanovic, Aleksandar Jovanovic, Tanja Nikolic, Miroslava Jasovic-Gasic
JournalProgress in neuro-psychopharmacology & biological psychiatry (Prog Neuropsychopharmacol Biol Psychiatry) Vol. 43 Pg. 1-6 (Jun 03 2013) ISSN: 1878-4216 [Electronic] England
PMID23200828 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2012 Elsevier Inc. All rights reserved.
Chemical References
  • Antidepressive Agents
  • Cytokines
  • Interleukin-6
  • Tumor Necrosis Factor-alpha
Topics
  • Adult
  • Age of Onset
  • Analysis of Variance
  • Antidepressive Agents (therapeutic use)
  • Cross-Sectional Studies
  • Cytokines (blood)
  • Depressive Disorder, Major (metabolism, psychology, therapy)
  • Disease Progression
  • Educational Status
  • Female
  • Humans
  • Interleukin-6 (blood)
  • Male
  • Middle Aged
  • Psychiatric Status Rating Scales
  • Smoking (adverse effects, psychology)
  • Socioeconomic Factors
  • Suicidal Ideation
  • Tumor Necrosis Factor-alpha (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: